Seed/Series A · $175MKorsana Biosciences
Oral therapeutics for allergies and autoimmune diseases
ImmunologyOral TherapeuticsClinical Stage
korsana.com →
The Pill vs. the Needle
If you have severe asthma or eczema, your treatment options are limited: expensive injectable biologics that can cost $30,000+ per year, require regular clinic visits, and come with needles. Korsana Biosciences is developing oral small molecules that target the same biological pathways — specifically STAT6, a key driver of allergic inflammation — but in pill form.
Their $175 million combined Seed/Series A gives them the runway to push their lead candidates into human clinical trials by the end of 2026. If they work, the impact could be enormous: making cutting-edge immunology treatments available at a fraction of the cost, without injections, and without clinic visits.
Why Investors Are Excited
The market for asthma and atopic dermatitis biologics is worth over $40 billion and growing fast. An oral alternative that matches their efficacy would be a blockbuster drug. Korsana's approach — targeting STAT6 with small molecules — represents one of the most promising mechanisms in modern immunology.
About the Korsana Team
Korsana Biosciences is a clinical-stage biotech company developing oral small molecules that target STAT6, a key driver of allergic inflammation. The team is working to replace expensive injectable biologics — which can cost $30,000 or more per year — with simple pills for conditions like severe asthma and atopic dermatitis.
The Korsana team raised $175 million in a combined Seed/Series A, giving them the runway to push lead candidates into human clinical trials by the end of 2026. The company is tackling one of the most promising mechanisms in modern immunology with a small-molecule approach to a market dominated by injectable treatments.
If the oral STAT6 inhibitors prove effective, the impact could be enormous: making cutting-edge immunology treatments available at a fraction of the current cost, without injections, and without clinic visits. The addressable market for asthma and atopic dermatitis biologics alone is worth over $40 billion and growing.
2026
Clinical Trial Target
Sources: Public press releases, SEC and state business filings, published interviews, news coverage, and company disclosures.
FundedPulse